Head-To-Head Analysis: Biomerica (BMRA) versus Its Competitors

Biomerica (NASDAQ:BMRA) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its rivals? We will compare Biomerica to similar businesses based on the strength of its dividends, analyst recommendations, valuation, profitability, risk, earnings and institutional ownership.

Institutional and Insider Ownership

22.3% of Biomerica shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 12.3% of Biomerica shares are held by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Biomerica and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Biomerica	$4.34 million	-$3.78 million	-0.83
Biomerica Competitors	$1.89 billion	$136.85 million	5.95

Biomerica’s rivals have higher revenue and earnings than Biomerica. Biomerica is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Biomerica and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biomerica	-115.50%	-142.81%	-77.83%
Biomerica Competitors	-300.62%	-179.55%	-22.71%

Risk & Volatility

Biomerica has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500. Comparatively, Biomerica’s rivals have a beta of 5.41, suggesting that their average stock price is 441% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Biomerica and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomerica	1	0	0	0	1.00
Biomerica Competitors	4302	10596	18377	837	2.46

Biomerica currently has a consensus price target of $9.00, indicating a potential upside of 561.76%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.25%. Given Biomerica’s higher probable upside, research analysts plainly believe Biomerica is more favorable than its rivals.

Summary

Biomerica rivals beat Biomerica on 10 of the 13 factors compared.

About Biomerica

Biomerica, Inc. is a medical diagnostics company that develops, manufactures and commercializes products designed to help diagnose and manage gastrointestinal and other health conditions. Its offerings are intended for use by physicians, laboratories and consumers, depending on the product. The company’s principal product is inFoods IBS, a blood-based diagnostic and therapeutic system designed to identify foods that may contribute to symptoms associated with irritable bowel syndrome. The system is intended to support a personalized dietary program under the direction of a healthcare professional.